![]() |
市場調查報告書
商品編碼
2068751
低溫運輸運輸市場預測至2034年-按溫度區域、運輸方式、服務類型、最終用戶產業和地區分類的全球分析Cold Chain Transport Market Forecasts to 2034 - Global Analysis By Temperature Range (Frozen, Deep Frozen, Chilled, and Controlled Ambient), Mode of Transport, Service Type, End-Use Industry, and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球低溫運輸運輸市場規模將達到 4,452 億美元,並在預測期內以 10.6% 的複合年成長率成長,到 2034 年將達到 9,969 億美元。
低溫運輸運輸是指對生鮮產品進行溫度控制的供應鏈管理,確保產品從原產地到目的地始終保持在指定的溫度範圍內。這個專業物流領域對於維持食品、藥品、化學品和其他溫度敏感型貨物的品質、安全性和保存期限至關重要。市場涵蓋冷藏車、冷藏貨櫃、冷藏倉庫以及應用於多種運輸方式的監控系統,服務於從農業和食品加工到生物技術和醫療保健等眾多行業。
全球對生鮮食品的需求不斷成長
消費者偏好的轉變導致生鮮食品、冷凍和已調理食品食品的需求日益成長,這些食品都需要溫控物流,從而顯著推動了市場擴張。在開發中國家,都市化加快和可支配收入增加,使得消費模式轉向富含蛋白質的飲食,包括乳製品、肉類和魚貝類,而這些都依賴可靠的低溫運輸基礎設施。超級市場和大賣場等有組織的零售業態在全球範圍內的擴張,需要複雜的低溫運輸網路來維持產品在廣泛分銷管道中的品質。此外,線上生鮮配送服務的日益普及,進一步增加了對「最後一公里」低溫運輸解決方案的需求,這些解決方案能夠在配送的最後階段保持產品品質。
高昂的營運成本和基礎設施成本
低溫運輸運輸需要大量資金投入專用設備,並持續消耗能源,嚴重阻礙了市場成長。冷藏車、溫控貨櫃、冷庫和即時監控系統都需要大量的初始投資,小規模物流業者難以負擔。在整個運輸過程中保持精確的溫度範圍會帶來持續的運作負擔,特別是對於需要高度冷藏的冷凍和超冷凍貨物而言。此外,冷凍設備、緊急電源系統和溫度感測器的維護和維修成本也構成了新進入者的准入壁壘,限制了其在價格敏感型發展中市場的擴張。
擴大生物製藥和疫苗的分銷
隨著製藥業對敏感生物製藥的低溫物流需求日益成長,這為低溫運輸運輸的轉型提供了機會。 mRNA疫苗的成功分發(這些疫苗需要在-70°C的極低溫下儲存)證明了先進低溫運輸技術在拯救生命的治療方法中的可行性。隨著生物製藥、細胞療法和基因療法研發管線的不斷擴展,所有這些療法都需要配備冗餘監控和備份系統的專業溫控運輸。製藥公司正在積極尋找擁有成熟低溫運輸經驗的物流合作夥伴,這為投資低溫運輸能力並致力於遵守包括藥品良好分銷規範(GDP)在內的嚴格監管要求的企業創造了盈利空間。
供應鏈中斷與基礎設施脆弱性
此因素對低溫運輸運輸的可靠性構成重大威脅,因為溫度敏感型貨物對延誤或設備故障零容忍。氣候變遷加劇的極端天氣事件會擾亂公路、鐵路、航空和海運路線,使易腐貨物面臨因溫度波動而受損的風險。港口擁擠、勞資糾紛和地緣政治緊張局勢會導致貨物長時間滯留,超出溫度敏感型產品可承受的溫度範圍。與可以容忍一定延誤的乾貨不同,運輸途中冷藏設備的故障可能導致貨物完全損失,且無法挽回損失。應對這些脆弱性需要成本高昂的冗餘措施和全面的緊急時應對計畫,從而增加營運複雜性和保險成本。
新冠疫情大大加速了低溫運輸運輸市場的變革,疫苗配送物流的需求空前高漲。全球為運送數十億劑疫苗的全球行動,需要迅速提升超低溫低溫運輸的運力,尤其是mRNA疫苗的運輸能力。製藥公司、物流供應商和各國政府紛紛投入巨資建設專用冷凍庫、溫度監控設備和培訓人員,實現了基礎設施的持續改善。同時,疫情對傳統食品供應鏈造成的衝擊也凸顯了低溫運輸的脆弱性,促使各方加強對更具韌性系統的投入。在此期間累積的營運能力,持續服務於藥品分銷,並提升了所有溫度敏感型物流應用領域的行業標準。
在預測期內,「冷藏」細分市場預計將佔據最大的市場佔有率。
預計在預測期內,「冷藏」運輸領域將佔據最大的市場佔有率,這主要得益於大量生鮮食品需要在0至4°C之間進行溫度控制(無需冷凍)。此溫度範圍涵蓋新鮮農產品、乳製品、大多數已調理食品以及許多藥品,包括胰島素和某些疫苗。從農場、食品加工廠和製藥企業到物流中心和零售店的每日冷藏運輸量遠遠超過冷凍和超低溫冷凍運輸量。零售商不斷更新冷藏庫存,從而全年保持對冷藏運輸服務的穩定持續需求。這使得冷藏運輸成為低溫運輸運輸市場的商業性基礎。
預計在預測期內,航空運輸領域將呈現最高的複合年成長率。
在預測期內,受高價值、時效性強、溫控產品快速長途運輸需求的日益成長的推動,航空貨運領域預計將呈現最高的成長率。航空運輸對於藥品(尤其是生物製藥和臨床試驗材料)的運輸至關重要,能夠確保這些產品在緊迫的時限內送達全球各地。高價值易腐貨物,例如優質海鮮、異國水果和鮮切花,銷往國際市場,需要航空貨運才能提供的速度。專用於藥品的航空貨運網路不斷擴展,並在始發地和目的地機場提供溫控地面處理,從而實現可靠的門到門服務。隨著全球藥品貿易的擴張以及消費者對全年國際生鮮食品的需求,航空低溫運輸運輸正處於快速發展階段。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其高度發展的低溫運輸基礎設施、嚴格的食品安全法規以及集中的製藥製造地。該地區成熟的食品零售業擁有龐大的冷藏配送網路,服務於傳統門市和快速發展的電商食品平台。遍佈美國和波多黎各的大規模製藥生產設施為國內外市場創造了對溫控物流的穩定需求。 《食品安全現代化法案》和《藥品供應鏈安全法案》等法規結構要求在整個配送鏈中進行嚴格的溫度監控,使低溫運輸要求制度化。商業性需求和嚴格監管的結合,使北美保持了其市場領先地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於快速的都市化、中產階級可支配收入的成長以及有組織零售業的日益普及。在中國和印度,隨著各國政府認知到冷鏈基礎設施在減少收穫後食物浪費和提高糧食安全方面的重要性,對低溫運輸基礎設施的投資正以前所未有的速度成長。該地區對冷凍和冷藏加工食品的需求不斷成長,加上藥品生產能力的擴大,正在創造對低溫運輸運輸的持續需求。國際零售商和物流業者正在擴大其在東南亞國家(包括越南、泰國和印尼)的低溫運輸網路。隨著國內消費模式持續向生鮮食品和冷凍產品轉變,亞太地區正成為低溫運輸運輸服務成長最快的市場。
According to Stratistics MRC, the Global Cold Chain Transport Market is accounted for $445.2 billion in 2026 and is expected to reach $996.9 billion by 2034 growing at a CAGR of 10.6% during the forecast period. Cold chain transport refers to the temperature-controlled supply chain management of perishable goods, ensuring products remain within specified temperature ranges from origin to destination. This specialized logistics sector is essential for preserving the quality, safety, and shelf life of food products, pharmaceuticals, chemicals, and other temperature-sensitive items. The market encompasses refrigerated vehicles, containers, warehousing, and monitoring systems deployed across multiple transport modes, serving industries from agriculture and food processing to biotechnology and healthcare.
Growing demand for perishable food products globally
This factor is significantly driving market expansion as changing consumer preferences favor fresh, frozen, and prepared foods requiring temperature-controlled logistics. Rising urbanization and disposable incomes in developing economies have shifted consumption patterns toward protein-rich diets including dairy, meat, and seafood, all dependent on reliable cold chain infrastructure. The global expansion of organized retail formats such as supermarkets and hypermarkets necessitates sophisticated cold chain networks to maintain product quality across extended distribution channels. Additionally, the growing popularity of online grocery delivery services has intensified demand for last-mile cold chain solutions capable of preserving product integrity during final delivery stages.
High operational and infrastructure costs
This factor significantly restrains market growth as cold chain transport requires substantial capital investment in specialized equipment and ongoing energy expenditures. Refrigerated vehicles, temperature-controlled containers, cold storage facilities, and real-time monitoring systems demand significant upfront investment that smaller logistics providers cannot easily afford. Energy costs for maintaining precise temperature ranges throughout transit represent a continuous operational burden, particularly for frozen and deep-frozen shipments requiring intensive refrigeration. Maintenance and repair of refrigeration units, backup power systems, and temperature sensors add further expenses, creating barriers to entry for new participants and limiting expansion in price-sensitive developing markets.
Expansion of biopharmaceutical and vaccine distribution
This factor presents transformative opportunities for cold chain transport as the pharmaceutical industry increasingly requires ultra-low temperature logistics for sensitive biological products. The successful distribution of mRNA vaccines, which require storage at temperatures as low as minus 70 degrees Celsius, has demonstrated the viability of advanced cold chain capabilities for life-saving therapies. Growing pipelines of biologic drugs, cell therapies, and gene therapies all demand specialized temperature-controlled transport with redundant monitoring and backup systems. Pharmaceutical companies are actively seeking logistics partners with validated cold chain expertise, creating lucrative opportunities for providers who invest in deep-frozen capabilities and compliance with stringent regulatory requirements including Good Distribution Practices.
Supply chain disruptions and infrastructure vulnerabilities
This factor poses significant threats to cold chain transport reliability, as temperature-sensitive shipments have zero tolerance for delays or equipment failures. Extreme weather events intensified by climate change can disrupt road, rail, air, and sea transport routes, potentially exposing perishable cargo to damaging temperature fluctuations. Port congestions, labor strikes, and geopolitical tensions can create extended holding periods that exceed the temperature tolerance windows of sensitive products. Refrigeration equipment failures during transit can result in complete cargo loss with no salvage value, unlike dry goods that may tolerate some delay. These vulnerabilities necessitate costly redundancy measures and comprehensive contingency planning, increasing operational complexity and insurance expenses.
The COVID-19 pandemic dramatically accelerated cold chain transport market evolution through unprecedented demand for vaccine distribution logistics. The global effort to deliver billions of vaccine doses across every continent required rapid expansion of ultra-low temperature cold chain capacity, particularly for mRNA vaccines. Pharmaceutical companies, logistics providers, and governments invested heavily in specialized freezers, temperature monitors, and trained personnel, creating lasting infrastructure improvements. Simultaneously, pandemic-related disruptions to traditional food supply chains highlighted cold chain vulnerabilities, driving investment in more resilient systems. The operational capabilities developed during this period continue serving pharmaceutical distribution and have elevated industry standards for all temperature-sensitive logistics applications.
The Chilled segment is expected to be the largest during the forecast period
The Chilled segment is expected to account for the largest market share during the forecast period, driven by the vast volume of perishable products requiring temperatures between zero and four degrees Celsius without freezing. This temperature range encompasses the majority of fresh produce, dairy products, prepared foods, and many pharmaceutical products including insulin and certain vaccines. The sheer daily volume of chilled shipments from farms, food processors, and pharmaceutical manufacturers to distribution centers and retail locations far exceeds frozen or deep-frozen volumes. Retailers maintain continuous chilled inventory turnover, generating consistent recurring demand for chilled transport services throughout the year, establishing this segment as the commercial foundation of the cold chain transport market.
The Air segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Air segment is predicted to witness the highest growth rate, fueled by the increasing need for rapid, long-distance transport of high-value and time-sensitive temperature-controlled products. Pharmaceutical shipments, particularly biologic drugs and clinical trial materials, require air transport to reach global destinations within strict time windows. High-value perishable goods including premium seafood, exotic fruits, and cut flowers destined for international markets demand the speed that only air freight can provide. The expansion of dedicated pharmaceutical air cargo networks with temperature-controlled ground handling at both origin and destination airports enables reliable door-to-door service. As global pharmaceutical trade grows and consumers demand international fresh products year-round, air cold chain transport continues its rapid expansion trajectory.
During the forecast period, the North America region is expected to hold the largest market share, supported by a highly developed cold chain infrastructure, stringent food safety regulations, and a concentrated pharmaceutical manufacturing presence. The region's mature grocery retail sector maintains extensive refrigerated distribution networks serving both traditional stores and rapidly expanding e-commerce grocery platforms. Significant pharmaceutical production facilities across the United States and Puerto Rico generate consistent demand for temperature-controlled logistics to domestic and international markets. Regulatory frameworks including the Food Safety Modernization Act and the Drug Supply Chain Security Act mandate strict temperature monitoring throughout distribution, institutionalizing cold chain requirements. This combination of commercial demand and regulatory enforcement sustains North America's market leadership.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapid urbanization, rising middle-class disposable incomes, and expanding organized retail penetration. China and India are witnessing unprecedented growth in cold chain infrastructure investments as governments recognize its importance for reducing post-harvest food losses and improving food security. The region's increasing demand for frozen and chilled convenience foods, coupled with growing pharmaceutical manufacturing capabilities, creates sustained cold chain transport requirements. International retailers and logistics providers are expanding cold chain networks throughout Southeast Asian nations including Vietnam, Thailand, and Indonesia. As domestic consumption patterns continue shifting toward perishable and frozen products, Asia Pacific emerges as the fastest-growing market for cold chain transport services.
Key players in the market
Some of the key players in Cold Chain Transport Market include Lineage Inc., Americold Logistics, LLC, A.P. Moller - Maersk A/S, United Parcel Service, Inc., Deutsche Post AG, Kuehne + Nagel International AG, DSV A/S, NewCold Cooperatief U.A., Nichirei Corporation, Snowman Logistics Limited, United States Cold Storage, Inc., Burris Logistics, Inc., Tippmann Group, Sonoco Products Company, Wabash National Corporation, CEVA Logistics AG, ColdEX Logistics Pvt. Ltd., VersaCold Logistics Services, Inc., Dachser SE, and Scan Global Logistics A/S.
In May 2026, Maersk announced the launch of its first dedicated reefer rail service from Hyderabad to Mumbai to boost pharmaceutical cold chain exports, alongside moving pharma clients from air to ocean freight to lower carbon footprints.
In May 2026, NewCold announced a massive expansion of its integrated UK transport and automated cold storage operations across Corby and Wakefield, processing over 100,000 pallet movements weekly with a 99.65% delivery success rate.
In May 2026, Americold announced a new $1.3 billion joint venture with global real estate investor EQT to strengthen its balance sheet and fund customer-driven retail and store-support cold storage development.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.